|THCV||anti-psychotic,schitzophrenia in vitro via experiment||The phytocannabinoid, ??-tetrahydrocannabivarin, can act through 5-HT1A receptors to produce antipsychotic effects.||Mar 2015|
Action Pathway: 5-HT1A|
Our findings suggest that THCV can enhance 5-HT1A receptor activation, and that some of its apparent antipsychotic effects may depend on this enhancement. We conclude that THCV has therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of schizophrenia.
|CBD||schitzophrenia in humans via placebo trial (n=88)||Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.||Mar 2018|
Ingestion Method: 1000mg CBD|
Positive After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=-1.4, 95% CI=-2.5, -0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=-0.5, 95% CI=-0.8, -0.1) and as not severely unwell (CGI-S: treatment difference=-0.3, 95% CI=-0.5, 0.0) by the treating clinician.